Ibat inhibitors for the treatment of liver diseases

A method for the treatment of non-alcoholic steatohepatitis (NASH), comprising orally administering to a subject in need of such treatment a therapeutically effective amount of an IBAT inhibitor, wherein the IBAT inhibitor is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio -8-(N-{(R)-1′-phenyl-1′-[N′-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3 ,4, 5-tetrahydro-1,5-benzothiazepine, or a pharmaceutically acceptable salt thereof.

A method for the treatment of a non-alcoholic steatohepatitis (NASH), comprising orally administering to a subject in need of such treatment a therapeutically effective amount of an IBAT inhibitor, wherein the IBAT inhibitor is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1′-phenyl-1′[N′-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy) -2,3,4,5-tetrahydro-1,5-benzothiazepine, or a pharmaceutically acceptable salt thereof, and ursodeoxycholic acid or nor-ursodeoxycholic acid.

A method for the treatment of non-alcoholic fatty liver disease (NAFLD), comprising orally administering to a subject in need of such treatment a therapeutically effective amount of an IBAT inhibitor, wherein the IBAT inhibitor is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1′-phenyl-1′[N′-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy) -2,3,4,5-tetrahydro-1,5-benzothiazepine, or a pharmaceutically acceptable salt thereof

A method for the treatment of a non-alcoholic fatty liver disease (NAFLD), comprising orally administering to a subject in need of such treatment a therapeutically effective amount of an IBAT inhibitor, wherein the IBAT inhibitor is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1′-phenyl-1′[N′-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy) -2,3,4,5-tetrahydro-1,5-benzothiazepine, or a pharmaceutically acceptable salt thereof, and ursodeoxycholic acid or nor-ursodeoxycholic acid.